Some cancers may not require immediate treatment, from prostate cancer to thyroid tumors. Medical experts share when ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

A low prognostic nutritional index may indicate a reduced response to ICIs due to diminished hepatic function and systemic inflammation.

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 6, 2026, Alpha Tau Medical reported final results from its ...

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...

Participants of the IAEA's MEDBIODOSE coordinated research project at the first research coordination meeting in October 2017, Vienna, Austria ...

Here are the top 5 soft tissue sarcoma articles of 2025: ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

As of Monday, January 05, Zenas BioPharma, Inc.’s ZBIO share price has dipped by 53.83%, which has investors questioning if ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.